Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? · 1d ago
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12 · 09/17 14:05
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a
Benzinga · 09/16 11:05
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a Mechanistic Approach to Treating Narco...
GlobeNewswire · 09/16 11:00
Axsome Therapeutics Enrolls First Patient in Late-Stage Trial of AXS-12 in Narcolepsy
MT Newswires · 09/16 08:30
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Zacks · 09/15 14:26
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
BRIEF-Axsome Therapeutics Announces FDA Acceptance Of NDA For Migraine Treatment · 09/14 11:20
FDA Accepts Axsome's New Drug Application for Migraine Treatment - Shares Rise Pre-Bell
MT Newswires · 09/14 07:58
Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue? · 09/08 15:30
10 Biggest Price Target Changes For Monday
Barclays raised Affirm Holdings, Inc. (NASDAQ: AFRM) price target from $85 to $115. Affirm shares rose 37% to $93.00 in pre-market trading.
Benzinga · 08/30 11:44
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $225 to $180.
Benzinga · 08/30 10:21
--HC Wainwright Adjusts Price Target on Axsome Therapeutics to $180 From $225, Maintains Buy Rating
MT Newswires · 08/30 07:40
Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.
Zacks · 08/24 15:37
Axsome Might Still be Awesome for Your Portfolio
Axsome Therapeutics (AXSM) develops novel therapies for central nervous system (CNS) related disorders for which limited treatment options are available. The company’s portfolio of five CNS pipeline candidates —AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14—ar...
TipRanks · 08/24 13:41
Hot Stocks: PFE/BNTX COVID vaccine; EDIT rises on gene-editing data; MSGE revenue beat
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) took the spotlight in Monday's midday trading on news that U.S. authorities had given full approval to their COVID-19 vaccine. Both stocks rose on the
Seekingalpha · 08/23 16:47
BRIEF-Axsome Therapeutics Provides Update On The New Drug Application For Axs-05 For The Treatment Of Major Depressive Disorder · 08/23 12:44
Why Is Axsome Therapeutics (AXSM) Stock Shooting Higher On Monday?
Benzinga · 08/23 12:28
Axsome says U.S. FDA asks for no extra data for depression drug, shares surge
Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company's drug to treat depression as the agency continues to review it, sending shares of the drug developer surging 44% before the ...
Reuters · 08/23 12:17
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/23 12:12
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).